Renalytix (LON:RENX) Shares Down 3.2% – Time to Sell?

Shares of Renalytix Plc (LON:RENXGet Free Report) dropped 3.2% during trading on Thursday . The stock traded as low as GBX 7.20 ($0.09) and last traded at GBX 7.50 ($0.09). Approximately 194,880 shares were traded during trading, a decline of 55% from the average daily volume of 433,320 shares. The stock had previously closed at GBX 7.75 ($0.10).

Renalytix Stock Performance

The firm’s 50-day moving average price is GBX 8.23 and its 200 day moving average price is GBX 13.02. The company has a current ratio of 0.53, a quick ratio of 2.42 and a debt-to-equity ratio of 173.95. The company has a market cap of £12.86 million, a price-to-earnings ratio of -31.25 and a beta of 2.10.

Insider Activity at Renalytix

In other Renalytix news, insider Christopher H. B. Mills sold 83,696 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of GBX 8 ($0.10), for a total transaction of £6,695.68 ($8,429.66). 35.74% of the stock is currently owned by insiders.

About Renalytix

(Get Free Report)

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score.

Featured Articles

Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.